A woman who lost over two stone in just four months has revealed how she was able to quit weight-loss jabs for good by 'micro ...

The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

The number of people taking weight-loss injections is exploding. With more and more men going “on the needle”, here’s what ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or overweight.

Discover how tirzepatide benefits heart failure in obesity, and see why those with higher BMI may gain even more benefits.